CER: Who Can Say What, and When Can They Say It?

E.V.I.dently, November 2011 By Robert W. Dubois, MD, PhD, Chief Science Officer, National Pharmaceutical Council

With billions of dollars in comparative effectiveness research (CER) set for completion in coming years, there will be broader discussions about the findings and what those findings might mean for patients and other health care decision makers. A parallel discussion will be conducted around questions regarding who can discuss and share these CER findings publicly? Who has access to the data that was used to generate the CER? These are just some of the pressing questions that are being raised by health care stakeholders as CER becomes more prevalent. Let's take a closer look at these issues:

Access to Data

Today there are a number of databases that are mined for comparative effectiveness research and other health care studies. Some are proprietary databases operated by payers, academic research institutions, or the pharmaceutical industry, while others are taxpayer-funded and government operated (FDA AERS, NHANES). In anticipation of the wide range of CER, however, a number of new databases are being developed by both private and public sector organizations. 

What’s unclear is the nature of the access that will be granted to these new databases, particularly if different groups want to affirm or disprove the CER that was developed from that data or review the research methodology. In general, having access to this information could be important for optimal patient care management. With some oversight, broader access to public databases such as Sentinel and Janus, as well as databases funded by the Patient-Centered Outcomes Research Institute, could be a good start.

Communicating Information

The pharmaceutical industry is highly regulated when it comes to discussing health care information, while other groups have wide latitude—or even complete freedom—in what they can say. While there are valid reasons for the regulation of some communication (marketing messages and materials, for example), there also are instances where it would be in the greater interest of public health for the sponsor of a particular drug to be allowed to respond to research or easily correct misinformation beyond solicited medical information. When it comes to CER, would the industry be able to discuss or share those studies, or even call for corrections on ones with serious flaws?

Communicating to Physicians

CER will be further amplified through academic detailing initiatives, in which government or academic institutions train health experts to discuss CER with physicians. In the United States, the Agency for Healthcare Research and Quality is leading the multi-million dollar federal initiative that will start off by targeting 1,500 primary care physicians and health systems. The federal government is not alone in its efforts – states including Vermont, Pennsylvania, South Carolina and Maine have been conducting academic detailing for a number of years.

Additionally, CER information will be further disseminated via continuing medical education programs and payer review guides, which are currently in development.  

These programs can be useful in providing physicians and payers with information that they might not have been aware of otherwise. However, it is not clear as to where the checks and balances may exist in the oversight of government-sponsored detailing, in the same way it is required of industry. 

Challenges for Patients

There are thousands of pages of health information available on the Internet, in medical journals, and other sources. Sifting through the information is daunting for a health care professional, let alone a patient. With more information becoming available, it will be even more important to ensure that patients have access to a broad amount of correct, verified information and know where to find it.

Unfortunately, sometimes incorrect information is shared broadly—U.S. Rep. Michelle Bachmann’s recent public statements about a vaccine is just one example—and it can be difficult to quickly correct the misinformation and make sure that consumers are properly educated. Acting on poor or faulty information could lead to serious health consequences for patients.

What will it take to address these challenges? It’s too early to know for sure, but a decision on U.S. vs. Caronia, a case pending in the U.S. Court of Appeals for the Second Circuit, could have implications for the pharmaceutical industry. At issue in Caronia is whether the First Amendment protects the right of individuals to speak truthfully about off-label uses of FDA-approved products. The question is whether a decision in the case will have broader applicability to CER and other health-related studies.

Next Steps

The challenges related to conducting, disseminating and communicating CER won’t be solved overnight. But it is important to begin considering how these questions might be addressed, and to their credit, organizations like the Agency for Healthcare Research and Quality, are beginning to discuss these issues. To further the dialogue, NPC will be hosting a conference in early 2012 to explore the asymmetry of communications and data access issues in greater detail. It’s important to consider all of the aspects of this issue, because having the right information is critical for patients and health care providers.

For additional information on asymmetry, view our interviews with patients, health care and legal experts. 

Blog Post

CER Tweets of the Week (April 7-11, 2014)

Collaboration was a popular topic among comparative effectiveness research (CER) stakeholders on Twitter this week. They tweeted about the National...
YouTube Videos

Webinar: CER Collaborative: Tools You Can Use

Collaborative members hosted a webinar explaining how to use the tools they developed to create greater uniformity and transparency when evaluating...
Blog Post

CER Tweets of the Week (March 31- April 4, 2014)

This week, health care stakeholders on Twitter highlighted the many activities and sessions at the Academy of Managed Care Pharmacy’s (AMCP) 26th...
Blog Post

4/8 Webinar on CER Collaborative: Tools You Can Use

The CER Collaborative--a group formed by the Academy of Managed Care Pharmacy (AMCP), the International Society for Pharmacoeconomics and Outcomes...
Press Release

CER Collaborative Improving Health Outcomes Through New Comparative Evidence Tools

(Washington, DC, March 24, 2014)—Three peer-reviewed articles published in Value in Health offer important guidance to aid formulary decision-makers...
Press Release

NPC, UMD Study: Factors That Cause Different Treatment Responses Are Not Well Understood or Studied

Washington, DC, November 4, 2013—Although researchers and health care providers widely recognize that individuals with stage IV prostate cancer react...
Press Release

National Pharmaceutical Council Statement on Appointment of PCORI Board Chair

Washington, DC, September 19, 2013—The National Pharmaceutical Council (NPC) today released the following statement regarding the Government...
Press Release

NPC Comments on Appointment of AHRQ Director

Washington, DC, August 19, 2013—National Pharmaceutical Council (NPC) President Dan Leonard today released the following statement about the...
Commentary and Testimony Page

The State of CER and the Environment for Health Care Decision Making

This month, NPC released its third annual survey on stakeholders’ views on comparative effectiveness research (CER), “The State of Comparative...
Commentary and Testimony Page

Keeping Our Eye on the CER Ball

Until the cherry blossoms begin to bloom later next month, most of the water cooler conversations in Washington will focus on the federal budget....
Commentary and Testimony Page

Leveling the Playing Field? Could a Landmark Decision Alter the CER Communications Landscape?

A growing chorus of voices is publicly sharing data on the effectiveness of treatment options, but one viewpoint has long been shut out of key areas...
Commentary and Testimony Page

Living Up to Its Name? The Role of Patient-Centered Research

Anyone who has ever received bad news from his or her health care provider or held a loved one’s hand when a diagnosis was delivered can understand...
YouTube Videos

Webinar: CER Collaborative: Tools You Can Use

Collaborative members hosted a webinar explaining how to use the tools they developed to create greater uniformity and transparency when evaluating...
YouTube Videos

Comparative Effectiveness Research and Usability Criteria

Dr. John Whitney, Staff VP for Medical Policy Formation, WellPoint, Inc., explains how usability criteria can help health care stakeholders conduct...
YouTube Videos

Engaging Patients in the Research Process

Dr. Dan Mullins, professor of pharmaceutical health services research at the University of Maryland School of Pharmacy, explains why it is important...
YouTube Videos

Engaging Patients in Research

National Pharmaceutical Council President Dan Leonard explains why it's important to include patients throughout the research process. He says that...
Blog Post

CER Tweets of the Week (April 7-11, 2014)

Collaboration was a popular topic among comparative effectiveness research (CER) stakeholders on Twitter this week. They tweeted about the National...
Blog Post

CER Tweets of the Week (March 31- April 4, 2014)

This week, health care stakeholders on Twitter highlighted the many activities and sessions at the Academy of Managed Care Pharmacy’s (AMCP) 26th...
Blog Post

4/8 Webinar on CER Collaborative: Tools You Can Use

The CER Collaborative--a group formed by the Academy of Managed Care Pharmacy (AMCP), the International Society for Pharmacoeconomics and Outcomes...
Blog Post

CER Collaborative Rolls Out New Resources to Aid Formulary Decision-Making

A newly published series of peer-reviewed articles developed by the CER Collaborative will help formulary decision-makers more effectively evaluate...

Research

When Is Evidence Sufficient for Decision-Making?

This study outlines influential factors that impact how quickly new medical evidence is adopted and...
  •  
  • 1 of 20
  • >

Commentary & Testimony